Previous 10 | Next 10 |
Shares of Ardelyx (NASDAQ: ARDX) were soaring 8.9% as of 2:57 p.m. EDT on Wednesday. The big jump came after the company announced that its Japanese partner, Kyowa Kirin , has begun four late-stage clinical studies evaluating Ardelyx's lead candidate tenapanor in treating hyperp...
Ardelyx (ARDX) announces that its collaboration partner in Japan, Kyowa Kirin, has initiated four Phase 3 clinical studies evaluating tenapanor for hyperphosphatemia, triggering a $5M milestone payment to Ardelyx.Under the terms of the license agreement, which was signed in 2017, Ar...
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan Ardelyx to Receive a $5 Million Milestone Payment PR Newswire FREMONT, Calif. and WALTHAM, Mass. , April 14, 2021 /PR...
Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021 PR Newswire FREMONT, Calif. and WALTHAM, Mass. , April 12, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovat...
Gainers: [[AKBA]] +12.1%. [[SYBX]] +7.1%. [[ARDX]] +5.2%. [[ODT]] +4.9%. [[BYND]] +4.2%.Losers: [[FGEN]] -29.2%. [[FIXX]] -10.2%. [[MAXN]] -6.8%. [[IONS]] -5.8%. [[OM]] -5.4%. For further details see: AKBA, SYBX, FGEN and FIXX among after-hours movers
Brooklyn Immuno Therapeutics (BTX) +77%.Scienjoy Holding (SJ) +37% on strategic alliance with Snipp.Weidai (WEI) +26%.Elite Education Group International (EEIQ) +16%.Phunware (PHUN) +12%. as board authorizes bitcoin purchases for Blockchain Ecosystem Launch.Romeo Power (RMO) +12% as...
Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings PR Newswire FREMONT, Calif. and WALTHAM, Mass. , March 30, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasd...
Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors PR Newswire FREMONT, Calif. and WALTHAM, Mass. , March 15, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines t...
Ardelyx (ARDX): Q4 GAAP EPS of -$0.32 misses by $0.06.Revenue of $1.8M (-20.0% Y/Y) beats by $0.41M.Press Release For further details see: Ardelyx EPS misses by $0.06, beats on revenue
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Company well positioned for PDUFA date of April 29, 2021 and the potential launch of tenapanor PR Newswire FREMONT, Calif. and WALTHAM, Mass., March 8, 2021 /PRNews...
News, Short Squeeze, Breakout and More Instantly...
Why The Stock Market Is Down Today Why is the stock market down today? The final week of June and the second quarter has been jam-packed with economic data and inflation-related events. Fed Chair Jerome Powell recently said that the global economy has entered a “new world”...
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners PR Newswire HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from ...
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 PR Newswire WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a missio...